BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 30909989)

  • 1. Erratum to: MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
    Cao L; Wan Q; Li F; Tang CE
    BMB Rep; 2019 Mar; 52(3):226. PubMed ID: 30909989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
    Cao L; Wan Q; Li F; Tang CE
    BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.
    Qin K; Zhang F; Wang H; Wang N; Qiu H; Jia X; Gong S; Zhang Z
    BMB Rep; 2024 Feb; 57(2):122. PubMed ID: 38416113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.
    Qin K; Zhang F; Wang H; Wang N; Qiu H; Jia X; Gong S; Zhang Z
    BMB Rep; 2023 Jul; 56(7):416. PubMed ID: 37500559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
    Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
    Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S; Li Y; Cao X; Du J; Huang X
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
    Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
    J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
    Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
    Wang H; Zhang G; Zhang H; Zhang F; Zhou B; Ning F; Wang HS; Cai SH; Du J
    Eur J Pharmacol; 2014 Jan; 723():156-66. PubMed ID: 24333218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum to: Biphasic effects of TGFβ1 on BMP9-induced osteogenic differentiation of mesenchymal stem cells.
    Li RD; Deng ZL; Hu N; Liang X; Liu B; Luo J; Chen L; Yin L; Luo X; Shui W; He TC; Huang W
    BMB Rep; 2021 May; 54(5):284. PubMed ID: 34042565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
    Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
    Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SNAIL/miR-128 axis regulated growth, invasion, metastasis, and epithelial-to-mesenchymal transition of gastric cancer.
    Yu WW; Jiang H; Zhang CT; Peng Y
    Oncotarget; 2017 Jun; 8(24):39280-39295. PubMed ID: 28424413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-181b-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG.
    Yoo JO; Kwak SY; An HJ; Bae IH; Park MJ; Han YH
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1601-11. PubMed ID: 27102539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.
    Zhu X; Shen H; Yin X; Long L; Xie C; Liu Y; Hui L; Lin X; Fang Y; Cao Y; Xu Y; Li M; Xu W; Li Y
    Oncogene; 2016 Jan; 35(3):323-32. PubMed ID: 25867064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells.
    Hu SH; Wang CH; Huang ZJ; Liu F; Xu CW; Li XL; Chen GQ
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(23):5002-5008. PubMed ID: 27981531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling.
    Xu X; Zhu Y; Liang Z; Li S; Xu X; Wang X; Wu J; Hu Z; Meng S; Liu B; Qin J; Xie L; Zheng X
    Cell Death Dis; 2016 Feb; 7(2):e2088. PubMed ID: 26844702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
    Sadlecki P; Jóźwicki J; Antosik P; Grabiec M
    Tumour Biol; 2018 Jun; 40(6):1010428318784807. PubMed ID: 29952249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.